Schrödinger Inks AI Drug Discovery Deal with Bristol Myers Squibb
SDGR sits 44% above its 52-week low of $10.945.
Summary
Schrödinger announced a strategic collaboration with Bristol Myers Squibb to deploy its AI co-scientist Bunsen at scale within BMS's research organization. The deal expands a long-standing partnership, moving beyond routine software licensing to large-scale integration of Bunsen and RetroSynth for agentic drug discovery. This follows Schrödinger's recent $57 million payment from Eli Lilly's acquisition of Ajax Therapeutics, reinforcing the commercial traction of its platform. The collaboration validates Schrödinger's AI-driven approach and could lead to broader adoption across the pharmaceutical industry. Financial terms were not disclosed, but the agreement signals deepening relationships with major pharma partners.
At the time of this announcement, SDGR was trading at $15.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $10.95 to $23.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.